Immunone Inc. (IMNM:NASDAQ) has entered into an agreement to acquire preclinical antibody-drug conjugate (ADC) asset APN-497444 and associated intellectual property from Atreca Inc. (BCEL:NASDAQ) in a deal that underscores Immunome's focus on expanding its ADC pipeline, noted Wedbush analysts Dr. David Nierengarten, David Carlson, Dennis Pak, and Dr. Martin Fan in a December 26 research note.
Under the terms of the purchase deal, Immunome will pay Atreca US$12.5 million upfront and up to US$7 million tied to future APN-497444 clinical milestones. Initial data on the ADC candidate presented last year showed potential utility in ovarian, lung, colorectal, pancreatic, and esophageal cancers.
"We view this purchase as a positive for Immunome and further emphasizes its focus on the development of novel ADCs," the Wedbush analyst team commented.
They maintain an Outperform rating on Immunome shares with a US$12 price target. This target is based on a sum-of-parts net present value model for Immunome's assets and implies over 25% upside from the current US$9.39 share price.
The Atreca asset acquisition provides Immunome with additional preclinical ADC programs to complement lead clinical asset IMM-ONC-01 as it aims to establish itself as an emerging player in antibody-drug conjugates.
|Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for Wedbush Securities, Immunome Inc., December 26, 2023
Analyst Certification We, David Nierengarten, David Carlson, Dennis Pak and Martin Fan, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.
Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of Atreca, Inc.. 4. WS has received compensation for investment banking services from Immunome, Inc. within the last 12 months. 5. WS provided Immunome, Inc. with investment banking services within the last 12 months. 6. WS is acting as a financial advisor for Immunome, Inc..
Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available:
Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to [email protected]. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.
OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.